title: Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
authors.forename: Paolo
authors.initials: P
authors.lastname: Anderlini
authors.forename: Sheetal
authors.initials: S
authors.lastname: Sheth
authors.forename: Krystal
authors.initials: K
authors.lastname: Hicks
authors.forename: Cindy
authors.initials: C
authors.lastname: Ippoliti
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D033581:Stem Cell Transplantation; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate